Liver Cancer/HCC
Liver Cancer/HCC
EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 25 April 2016 00:00
- Written by Liz Highleyman
Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history of HCC, according to research presented at the recent European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona. These findings underline the importance of ongoing liver cancer monitoring even after successful hepatitis C treatment.
Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 15 March 2016 00:00
- Written by Liz Highleyman
Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.
AASLD 2015: People with Cirrhosis Cured of Hepatitis C Still Have Elevated Liver Cancer Risk
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 17 November 2015 00:00
- Written by Keith Alcorn
The burden of liver cancer and cirrhosis caused by hepatitis C virus (HCV) is likely to continue to grow in the U.S. despite curative treatment, and people who have cirrhosis at the time they are cured of hepatitis C will require long-term monitoring for liver cancer, studies presented this week at the AASLD Liver Meeting in San Francisco show.
Coverage of the 2015 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Monday, 23 November 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.
Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.
11/23/15
ASCO 2015: Does Hepatocellular Carcinoma Differ in People with Hepatitis B and C?
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 26 June 2015 00:00
- Written by Liz Highleyman
Liver cancer patients with hepatitis B at a large U.S. cancer center appeared to have worse disease status than those with hepatitis C, including larger tumors and more extensive liver involvement, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this month in Chicago. Prognosis for the 2 groups was similar, however.
Web Design and Development by